E. Dudnik, L. Ariel, K. Hod, H. Nechushtan, E. Hanovich, O. Rotem, M. Wollner, M. Guindy, M.A. Ben David
{"title":"P2.16-05 Durvalumab+EP in Advanced Large-Cell Neuroendocrine Carcinoma of Lung (aLCNEC): a Pilot Phase II study","authors":"E. Dudnik, L. Ariel, K. Hod, H. Nechushtan, E. Hanovich, O. Rotem, M. Wollner, M. Guindy, M.A. Ben David","doi":"10.1016/j.jtho.2023.09.666","DOIUrl":null,"url":null,"abstract":"Large-cell neuroendocrine carcinoma of lung (LCNEC) is a rare, high-grade neuroendocrine tumor sharing several features with small-cell lung cancer (SCLC.) Despite the relatively high objective response rate (ORR) with platinum+etoposide (EP) chemotherapy regimens typically used in the treatment of SCLC (37-52%), the responses are short-lived (12-month progression-free survival [PFS]-5%), and the survival is poor (median overall survival [OS]-10.2-11.1 months). Combinations of anti-PD-1/anti-PD-L1 immune checkpoint inhibitors (ICI) with EP are already incorporated into standard treatment algorithms in advanced SCLC based on the results of several phase III randomized clinical trials demonstrating a consistent OS benefit.","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jtho.2023.09.666","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Large-cell neuroendocrine carcinoma of lung (LCNEC) is a rare, high-grade neuroendocrine tumor sharing several features with small-cell lung cancer (SCLC.) Despite the relatively high objective response rate (ORR) with platinum+etoposide (EP) chemotherapy regimens typically used in the treatment of SCLC (37-52%), the responses are short-lived (12-month progression-free survival [PFS]-5%), and the survival is poor (median overall survival [OS]-10.2-11.1 months). Combinations of anti-PD-1/anti-PD-L1 immune checkpoint inhibitors (ICI) with EP are already incorporated into standard treatment algorithms in advanced SCLC based on the results of several phase III randomized clinical trials demonstrating a consistent OS benefit.
期刊介绍：
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
